Clinical Trial Update: Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports the completion of a study evaluating Panzem Nanocrystal Colloidal Dispersion in combination with temozolomide for recurrent gliob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Panzem Nanocrystal Colloidal Dispersion (NCD)
• Temodar (Temozolomide)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Recurrent Glioblastoma Multiforme | Phase 2 | Status: COMPLETED